NCT06439225View on ClinicalTrials.gov

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

PHASE3RecruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

March 31, 2030

Conditions
Metastatic Castration-resistant Prostate CancerMetastatic Prostate Cancer
Interventions
DRUG

Docetaxel

75mg/m2 q21 days

DRUG

Carboplatin

AUC5 q21 days

Trial Locations (8)

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

L6R 3J7

RECRUITING

William Osler Health System, Brampton

N2G 1G3

RECRUITING

Waterloo Regional Health Network (WRHN), Kitchener

N6A 5W9

RECRUITING

London Health Sciences Centre Research Inc., London

M4N 3M5

RECRUITING

Odette Cancer Centre, Toronto

M5G 2M9

RECRUITING

University Health Network, Toronto

H3T 1E2

RECRUITING

The Jewish General Hospital, Montreal

G1J 1Z4

RECRUITING

CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Canadian Cancer Trials Group

NETWORK